Ionis Pharmaceuticals has won regulatory approval for a first-of-its kind drug targeting a rare brain disease, but Wall Street is shrugging off the news for a simple reason.
Zilganersen, branded as Zanvastro, has been approved to treat both adult and pediatric patients with Alexander disease, a progressive neurological disorder. Typically appearing in early childhood, symptoms range from developmental delays and seizures to muscle weakness and speech difficulties. The condition carries a poor prognosis and a high mortality rate.
Zanvastro's approval fulfills a significant unmet need for a debilitating disorder. Regulators actively prioritized its development with the Food and Drug Administration awarding the treatment Orphan Drug, Fast Track, Breakthrough Therapy, and Rare Pediatric Disease designations over the past few months.
Given this, investors might expect shares to leap on the news. While the approval offers a groundbreaking new option for patients, Wall Street sees a clear drawback: an extremely small addressable market.
The exact size of the patient population is unknown, though medical literature notes just over 500 documented cases globally and an estimated prevalence of 1 in 2.7 million people. Wall Street isn't anticipating a blockbuster. William Blair analysts estimated in April that the drug will peak at $295 million in annual sales, well below the $1 billion blockbuster threshold.
Ionis shares ticked up slightly on Friday following the approval. While it may not be a windfall for shareholders, the medication is transformative for patients. Until now, treatment for Alexander disease was largely limited to managing symptoms, according to the company.
Unlike legacy treatments, Zanvastro targets the underlying cause of the disease by suppressing the production of glial fibrillary acidic protein, which otherwise accumulates in the brain due to a genetic mutation.
Zanvastro is administered as an injection once every three months. In a study earlier this year, patients who received a 50-milligram dose showed statistically significant improvements in walking speed, measured by a 10-meter walk test at 61 weeks.
A flush of rare-disease therapies has entered the market as drugmakers rush into areas of high unmet need. This also means steeper competition: Data from consulting firm Charles River Associates shows the number of rare diseases with multiple approved therapies has surged over the past decade, increasing from seven rare diseases with more than three approved therapies in 2015 to 54 in 2025.
Zanvastro joins an existing roster of commercialized Ionis drugs, which includes Tryngolza and two therapies developed alongside Biogen. The most recent approval before Zanvastro was a label expansion for Tryngolza in June, clearing the monthly injection to lower triglycerides and mitigate acute pancreatitis risk in adults with severe hypertriglyceridemia
The rare-disease space might be smaller, but it is shaping up to be a proving ground for next-generation platforms like Ionis' proprietary RNA technology. However, competition is intensifying quickly: Rival Arrowhead Pharmaceuticals is preparing to directly challenge Tryngolza's market dominance in severe hypertriglyceridemia.
Another Ionis asset, ION775, recently entered Phase 2b testing. J.P. Morgan analyst Jessica Fye views the drug as an opportunity to build on Tryngolza's momentum in severe hypertriglyceridemia-notably through a less frequent dosing schedule.
Barclays analyst Eliana Merle noted after meeting with management last month that executives sounded upbeat regrading Tryngolza's early launch in that indication. She believes the market is large enough to support multiple players, though Ionis' first-mover advantage "could be meaningful."
Ultimately, Tryngolza's commercial trajectory may prove far more meaningful for Ionis than the latest regulatory victory, as the drug tracks toward blockbuster status. While Zanvastro serves as a transformative milestone for patients, it's Tryngolza that will drive the bottom line for investors.
Comments